QM · rank #9 · 2026-09-04
SNT
GPW · PLN · $742M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +87.84% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $742M |
| Anchor (recent) Close on 2026-08-05 | $373.60 |
| Anchor (far) Close on 2025-08-05 | $198.89 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
SNT@GPW (Synektik) is a Polish healthcare-tech group that makes and distributes PET/CT radiopharmaceuticals and sells imaging/robotic surgery systems plus related IT and services across Poland and Central Europe.
Rationale
The screen looks credible because Synektik combines strong recent price momentum with high quality metrics — very high ROE, solid margins, rapid revenue/Ebitda growth, and a net cash balance — which fit a quality_momentum setup.
Material risks
- 1Reported profitability is flattered by the PLN ~261m Syn2bio spin-off gain, so ROE and net profit can normalize lower once the one-off is stripped out.
- 2The business is still heavily exposed to public-hospital and government tender spending in Poland/Central Europe, so budget cuts or contract delays could dent demand and growth visibility.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.